Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition for treating cancer comprising vaccinia virus and hydroxyurea as active ingredients

A technology of vaccinia virus and active ingredients, which is applied in the field of pharmaceutical compositions for the prevention or treatment of cancer, can solve problems such as persistent response or complete response, acute tumor necrosis, progressive disease, etc., and achieve excellent anticancer effect, excellent safety, effective cancer treatment

Pending Publication Date: 2022-04-12
拜耳诺克斯有限公司
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In multiple clinical studies of vaccinia virus-based oncolytic viruses, oncolytic virus therapy may result in acute tumor necrosis, durable responses, or complete responses, but in some cases, may lead to unpredictable outcomes (pharmacodynamic variability ), such as progressive disease or premature death

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating cancer comprising vaccinia virus and hydroxyurea as active ingredients
  • Pharmaceutical composition for treating cancer comprising vaccinia virus and hydroxyurea as active ingredients
  • Pharmaceutical composition for treating cancer comprising vaccinia virus and hydroxyurea as active ingredients

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0101] Preparation Example 1. Production of recombinant vaccinia virus (Wyeth VV tk- 、WR VV tk- )

preparation example 11

[0102] Preparation Example 1.1. Construction of Shuttle Plasmid Vector

[0103] For the production of recombinant vaccinia viruses lacking the thymidine kinase (TK) gene, wild-type vaccinia viruses, ie, the Wyeth strain (NYC Health Department) and the Western Reserve strain, were purchased from the American Type Culture Collection (ATCC). For recombination, the TK region in wild-type vaccinia virus was replaced using a shuttle plasmid vector containing the firefly luciferase reporter (p7.5 promoter) gene or the GFP gene.

preparation example 12

[0104] Preparation example 1.2. Production of recombinant vaccinia virus

[0105] To obtain recombinant virus, HeLa cells (ATCC) were grown at 4×10 per well 5 Cells were seeded in 6-well plates and cultured in EMEM medium containing 10% fetal bovine serum. Subsequently, wild-type vaccinia virus treatment was performed at an MOI of 0.05. After 2 hours, change the medium to EMEM medium containing 2% fetal bovine serum, and then use Xfect TM Polymer (Clonetech 631317, USA) was used to transfect cells with 4 μg of the shuttle plasmid vector constructed and linearized in Preparation 1.1. Incubate for 4 hours. Subsequently, the medium was replaced with EMEM medium containing 2% fetal calf serum, and cultured for another 72 hours. Finally, the infected cells were collected, and then the freeze-thaw was repeated 3 times. Subsequently, the cells were lysed by sonication, and the free recombinant vaccinia virus was obtained by the sucrose cushion method, which was named Wyeth VV t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising vaccinia virus and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer, comprising vaccinia virus and hydroxyurea as active ingredients according to the present invention, exhibits a higher anti-cancer effect and safety than conventional vaccinia virus alone administration. Therefore, the pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredients according to the present invention can be advantageously used for treating cancer.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating cancer, which comprises vaccinia virus and hydroxyurea as active ingredients. Background technique [0002] Oncolytic viruses have excellent tumor-specific targeting ability, proliferation ability in cancer cells and cancer cell killing ability. Recently, various clinical studies based on oncolytic viruses have been conducted. In 2015, the United States and Europe opened the era of the oncolytic virus field, and the herpes simplex virus-based oncolytic virus talimogene laherparepvec (T-Vec) was successfully commercialized as a treatment for advanced melanoma. [0003] Recently, the usefulness of oncolytic viruses exceeded their efficacy on their own, and viruses activated tumor immunity, thereby showing their potential as therapeutic agents in combination with another immunotherapeutic agent. Until 2000, which was the early stage of oncolytic virus development, t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/768A61K31/155A61K48/00A61K38/00A61P35/00
CPCA61K35/768A61P35/00C12N7/00C12N2710/24121C12N2710/24132C12N2710/24143A61K31/17A01K2207/12A01K2227/105A01K2267/0331A61K38/45C12Y207/01021A61K2300/00A61K38/162A61K38/1796A61K38/193A61K38/215A61K38/465A61K38/50A61K48/0008
Inventor 黄泰皓赵檬
Owner 拜耳诺克斯有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com